First Quadrant’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

First Quadrant’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-494	Closed	-$15K	–	874
2020 Q1	$15K	Sell	494 -3,661	-88%	-$124K	﹤0.01%	611
2019 Q4	$150K	Hold	4,155	–	–	0.01%	434
2019 Q3	$113K	Sell	4,155 -17,389	-81%	-$450K	0.01%	475
2019 Q2	$518K	Buy	21,544 +11,827	+122%	+$300K	0.04%	396
2019 Q1	$257K	Sell	9,717 -5,444	-36%	-$129K	0.02%	458
2018 Q4	$296K	Buy	15,161 +9,044	+148%	+$177K	0.02%	451
2018 Q3	$120K	Buy	6,117 +4,001	+189%	+$76.1K	﹤0.01%	693
2018 Q2	$35K	Buy	+2,116	New	+$32.3K	﹤0.01%	721

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

First Quadrant's HZNP Position: Q2 2020 in Review

First Quadrant sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2020, closing a stake of 494 shares — an estimated $15K sold.

First Quadrant first reported a position in HZNP in Q2 2018 and held it in 8 quarters. The position peaked at $518K in Q2 2019. 354 funds tracked by Wall St. Rank hold HZNP as of Q2 2020.

First Quadrant reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2020 after selling out during the quarter.
First Quadrant sold 494 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2020, an estimated $15K.
First Quadrant first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2018 and held it in 8 quarters.
First Quadrant's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $518K in Q2 2019.
354 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2020.

Based on First Quadrant's 13F filing for Q2 2020, filed 28 Jul 2020.